clinical trial · NCT05729139
Cemiplimab/Peg-Interferon-α in Advanced CSCC
Baptist Health South Florida·phase1·withdrawn
Cutaneous Squamous Cell CarcinomaSquamous Cell CarcinomaAdvanced Squamous Cell CarcinomaCemiplimab-RwlcPEG-IFN alfa-2a
brief summary
The primary purpose of this research study is to test the safety and possible harms of cemiplimab/peg-interferon-alpha, when it is given to participants at different dose levels. The researchers want to find out what effects (good and bad) cemiplimab/Peg-Interferon has on participants with advanced cutaneous squamous cell carcinoma (aCSCC) so that they can find the best dose to treat aCSCC and reduce side effects as much as possible.
started
Jul 1, 2023
primary completion
Jul 1, 2026
completion
Jul 1, 2028
last updated
Aug 9, 2023
official title
Cemiplimab/PEG-Interferon-α Combination for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol